Therapy of moderate-to-severe plaque psoriasis

Abstract

Psoriasis therapy is an acute issue in modern medicine. To date, much progress has been made in the field of genetically engineered biological therapy (GEBT) for psoriatic disease. The new treatment paradigm was made possible by the continuous advancement of understanding of the pathophysiology of the disease. GEBT represents an evolved treatment regimen in which targeted immunomodulation has led to significant improvements in the safety and efficacy of biological agents. Understanding the key role of interleukin-23 (IL) in the pathogenesis of psoriasis has led to the development of new drugs. Risankizumab is a humanised monoclonal antibody – immunoglobulin class G1 – specifically targeted at cytokine IL-23 inhibition by binding to its subunit p19. The efficacy and safety of the agent have been demonstrated both by the results of clinical trials and studies of real clinical practice. The article presents key data on the applicability of the drug risankizumab, and describes the clinical experience of managing a patient with psoriasis and aggravated comorbid conditions. It is currently known that a significant problem in the management of patients receiving GEBT is the presence of comorbid diseases. Difficulty in optimal treatment control, decreased response to therapy and increased risks of adverse events have all been noted. This study confirms the efficacy and safety of risankizumab therapy in patients with psoriasis and comorbidities. Thus, risankizumab is a promising drug for the treatment of moderate and severe forms of psoriasis, its use can significantly improve the quality of life of patients suffering from this disease.